Login to Your Account



CEO: 'All Bets Are Off'

2012 AdCom Deals New Blow To Obesity; Contrave on Hold

By Jennifer Boggs


Monday, June 6, 2011
Back in 2008, the FDA hit developers of diabetes drugs with new guidance requiring large and costly cardiovascular outcomes study, putting several late-stage programs in limbo. Now obesity drugmakers could find themselves facing the same fate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription